These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22025648)

  • 21. Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti-viral drugs as an example.
    Rawson NS
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1072-9. PubMed ID: 19650154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Public prescription drug plan coverage for antiretrovirals and the potential cost to people living with HIV in Canada: a descriptive study.
    Yoong D; Bayoumi AM; Robinson L; Rachlis B; Antoniou T
    CMAJ Open; 2018; 6(4):E551-E560. PubMed ID: 30482757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access.
    Burden AM; Tadrous M; Calzavara A; Cadarette SM
    Osteoporos Int; 2015 May; 26(5):1525-33. PubMed ID: 25603794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost shifting and timeliness of drug formulary decisions in atlantic Canada.
    Scobie AC; Mackinnon NJ
    Healthc Policy; 2010 Feb; 5(3):100-14. PubMed ID: 21286272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis.
    Lexchin J
    BMJ Open; 2018 Aug; 8(8):e023605. PubMed ID: 30166310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
    Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
    Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.
    Herder M; Krahn TM
    Healthc Policy; 2016 May; 11(4):70-81. PubMed ID: 27232238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health Canada's use of its priority review process for new drugs: a cohort study.
    Lexchin J
    BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An analysis of redactions in Canada's Common Drug Review Clinical Review Reports and how they relate to the patients' voice.
    Soprovich A; El Kurdi S; Eurich DT
    BMJ Open; 2017 Sep; 7(9):e015497. PubMed ID: 28893743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of the Cancer Drug Funding Process in Canada.
    Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
    Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of foreign-trained physicians to Canada.
    Baerlocher MO
    Clin Invest Med; 2006 Jun; 29(3):151-3. PubMed ID: 17058433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are there geographical disparities in access to liver transplantation in Atlantic Canada?
    Renfrew PD; Molinari M
    Can J Gastroenterol; 2012 Oct; 26(10):705-10. PubMed ID: 23061063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
    McLeod L; Bereza BG; Shim M; Grootendorst P
    Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Canadian status of "drugs to avoid" in 2017: a descriptive analysis.
    Lexchin J
    CMAJ Open; 2018; 6(3):E430-E435. PubMed ID: 30266781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Public drug plan coverage for children across Canada: a portrait of too many colours.
    Ungar WJ; Witkos M
    Healthc Policy; 2005 Sep; 1(1):100-22. PubMed ID: 19308106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A jurisdictional review of the legislation governing informed consent by chiropractors across Canada.
    Boucher PB; Brousseau D; Chahine S
    J Can Chiropr Assoc; 2016 Mar; 60(1):73-80. PubMed ID: 27069269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.
    Woon DTS; Chandrasekar T; Aaron L; Basappa NS; Chi KN; Conter HJ; Gotto G; Hotte SJ; Malone S; Saad F; Shayegan B; Park-Wyllie L; Hamilton RJ
    Can Urol Assoc J; 2018 Oct; 12(10):328-336. PubMed ID: 29688882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic impact of delays in listing decisions by provincial drug plans after a positive Common Drug Review recommendation: the case of a smoking-cessation treatment.
    Paradis PE; Mishagina N; Carter V; Raymond V
    Healthc Q; 2012; 15(2):52-60. PubMed ID: 22688206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.